Pressed Sanofi CEO Hopes For Positive Dupixent Launch, Praluent Ruling
Sanofi's CEO Olivier Brandicourt's reassuring 2017 guidance relies on continued cost savings, a successful launch of its Dupixent biologic, and winning a US legal case that threatens its PCSK9 inhibitor Praluent.
You may also be interested in...
Sanofi Builds Blood Disorder Specialty With Bioverativ Buy
The French drug maker is making a big splash into blood disorders with the $11.6bn acquisition of hemophilia specialist Bioverativ. Eloctate and Alprolix are young and growing brands, but the competition in hemophilia is fierce, which means Bioverativ's pipeline will also need to deliver to justify the premium price.
Sanofi/Regeneron Choose Access Over Price With Dupixent Launch
The FDA approved the IL-4/IL-13 inhibitor March 28 in a win for Sanofi and Regeneron. The companies set the biologic's price at $37,000 per year, which is lower than many biologics on the market for psoriasis.
Sponsors Flesh Out Profiles of New Dermatology Drugs At AAD Meeting
Additional data for J&J's guselkumab, Regeneron/Sanofi's Dupixent, Lilly's Taltz and UCB/Dermira's Cimzia featured at the American Academy of Dermatology meeting in Orlando, Fla. March 3-7.